When antibody production and conjugation span different sites and scales, additional handoffs can introduce tech transfer complexity and scale-dependent variability. A strong antibody foundation, CQA visibility, and process understanding can help support quality and scalability from development to manufacturing.
Our latest infographic explores how Samsung Biologics approaches these challenges through:
✅ Large-scale antibody manufacturing experience
✅ Dedicated bioconjugation infrastructure
✅ Process optimization supporting scale-up and technology transfer
✅ Analytical data showing consistent DAR distribution across development and pilot scales
Take a closer look at how we support ADC and other antibody-based conjugate programs.
When antibody production and conjugation span different sites and scales, additional handoffs can introduce tech transfer complexity and scale-dependent variability. A strong antibody foundation, CQA visibility, and process understanding can help support quality and scalability from development to manufacturing.
Our latest infographic explores how Samsung Biologics approaches these challenges through:
✅ Large-scale antibody manufacturing experience
✅ Dedicated bioconjugation infrastructure
✅ Process optimization supporting scale-up and technology transfer
✅ Analytical data showing consistent DAR distribution across development and pilot scales
Take a closer look at how we support ADC and other antibody-based conjugate programs.
- Attached
Related Content